- Home
- WST vs EQR Comparison
WST vs EQR Comparison
Compare WST & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WST
- EQR
- Stock Information
- Founded
- WST 1923
- EQR 1993
- Country
- WST United States
- EQR United States
- Employees
- WST N/A
- EQR N/A
- Industry
- WST Medical/Dental Instruments
- EQR Real Estate Investment Trusts
- Sector
- WST Health Care
- EQR Real Estate
- Exchange
- WST Nasdaq
- EQR Nasdaq
- Market Cap
- WST 15.2B
- EQR 27.2B
- IPO Year
- WST N/A
- EQR 1993
- Fundamental
- Price
- WST $213.06
- EQR $69.97
- Analyst Decision
- WST Strong Buy
- EQR Buy
- Analyst Count
- WST 6
- EQR 16
- Target Price
- WST $349.00
- EQR $78.69
- AVG Volume (30 Days)
- WST 977.3K
- EQR 2.0M
- Earning Date
- WST 04-24-2025
- EQR 04-29-2025
- Dividend Yield
- WST 0.39%
- EQR 3.96%
- EPS Growth
- WST N/A
- EQR 8.50
- EPS
- WST 6.37
- EQR 2.62
- Revenue
- WST $2,895,800,000.00
- EQR $3,010,100,000.00
- Revenue This Year
- WST $1.24
- EQR $6.07
- Revenue Next Year
- WST $6.56
- EQR $4.33
- P/E Ratio
- WST $33.62
- EQR $26.70
- Revenue Growth
- WST N/A
- EQR 3.81
- 52 Week Low
- WST $187.43
- EQR $59.41
- 52 Week High
- WST $372.79
- EQR $78.83
- Technical
- Relative Strength Index (RSI)
- WST 48.76
- EQR 52.92
- Support Level
- WST $204.79
- EQR $69.96
- Resistance Level
- WST $221.42
- EQR $71.04
- Average True Range (ATR)
- WST 7.01
- EQR 1.23
- MACD
- WST 1.16
- EQR 0.18
- Stochastic Oscillator
- WST 56.77
- EQR 43.75
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 311 apartment communities with around 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.